Healthcare
•3734 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3734)
| Company | Market Cap | Price |
|---|---|---|
|
TMCI
Treace Medical Concepts, Inc.
Treace's core bunion correction systems are surgical instruments/devices used in operative procedures.
|
$123.61M |
$1.93
+3.21%
|
|
NYXH
Nyxoah S.A.
Genio is a neuromodulation implant system (implantable medical device) for obstructive sleep apnea.
|
$122.40M |
$3.26
-0.61%
|
|
CRDF
Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company focused on oncology therapeutics, with its lead asset targeting cancer (onvansertib).
|
$121.25M |
$1.80
+6.80%
|
|
AVHHL
AVITA Medical, Inc.
AVITA Medical’s core offerings are wound care devices and dermal matrices (RECELL system, RECELL GO, PermeaDerm, Cohealyx) used in wound management, fitting the Wound Care Devices category.
|
$119.99M |
$0.79
|
|
CNFN
CFN Enterprises Inc.
CNFN's Ranco segment operates as a contract manufacturer/co-packer and white-label producer for clients.
|
$118.69M |
$1.00
|
|
QDMI
QDM International Inc.
Health/medical insurance products are distributed via the company’s insurance brokerage activities.
|
$118.03M |
$69.92
|
|
PEPG
PepGen Inc.
PepGen's PGN-EDODM1 is an oligonucleotide therapeutic targeting DM1, aligning directly with Oligonucleotide Therapeutics.
|
$116.87M |
$1.72
+2.69%
|
|
FATE
Fate Therapeutics, Inc.
Fate develops oncology-focused immunotherapies, aligning with Biotech - Oncology.
|
$116.48M |
$1.01
|
|
NNBR
NN, Inc.
Precision medical device components manufacturing, including implant-related parts (Medical Device Components).
|
$116.45M |
$2.31
+12.99%
|
|
SKIN
The Beauty Health Company
High-margin disposable consumables (tips, solutions, serums) sold for Hydrafacial devices create a recurring revenue stream, matching Medical Device Consumables.
|
$116.37M |
$0.91
+1.67%
|
|
RANI
Rani Therapeutics Holdings, Inc.
RaniPill is the core drug-delivery platform enabling oral administration of biologics, central to the company's offering.
|
$116.21M |
$0.96
+4.11%
|
|
ONCY
Oncolytics Biotech Inc.
Pelareorep is an oncolytic virus immunotherapy developed by Oncolytics Biotech, placing the company in Biotech - Oncology.
|
$116.07M |
$1.11
+4.72%
|
|
ASRT
Assertio Holdings, Inc.
ROLVEDON and related oncology-supportive care products position Assertio in Biotech - Oncology as its growth drivers.
|
$115.57M |
$18.02
|
|
KRRO
Korro Bio, Inc.
KRRO's core offering is its OPERA oligonucleotide platform enabling RNA editing therapeutics (oligonucleotide-based editing).
|
$113.91M |
$12.18
+0.66%
|
|
AARD
Aardvark Therapeutics, Inc. Common Stock
ARD-101 and ARD-201 are oral small-molecule therapeutics targeting satiety pathways for metabolic and rare-disease indications.
|
$113.87M |
$5.24
+5.01%
|
|
RPTX
Repare Therapeutics Inc.
Core company focus is oncology therapeutics with a synthetic lethality approach (Biotech - Oncology).
|
$113.84M |
$2.65
-0.19%
|
|
SEER
Seer, Inc.
SP100 instrument and related proteomics hardware qualify as Diagnostic Equipment.
|
$111.58M |
$2.00
-2.20%
|
|
WW
WW International, Inc.
WW operates WW Clinic and integrated weight health services, including clinical care delivery.
|
$109.66M |
$10.96
+2.72%
|
|
ALDX
Aldeyra Therapeutics, Inc.
Lead reproxalap for dry eye disease is an ophthalmic drug, representing a direct product in ophthalmology.
|
$108.29M |
$1.81
+0.56%
|
|
IFRX
InflaRx N.V.
Vilobelimab is an anti-C5a monoclonal antibody, making InflaRx's core product line Monoclonal Antibody Therapeutics.
|
$107.72M |
$1.59
+32.50%
|
|
GNLX
Genelux Corporation
Genelux focuses on oncology-focused viral immunotherapies, categorized under Biotech - Oncology.
|
$106.16M |
$2.79
+0.54%
|
|
UNCY
Unicycive Therapeutics, Inc.
Lead programs Oxylanthanum Carbonate (OLC) and UNI-494 are oral small-molecule therapeutics targeting kidney disease and hyperphosphatemia/acute kidney injury.
|
$106.15M |
$6.21
+3.41%
|
|
ICAD
iCAD, Inc.
iCAD operates in the Medical Imaging domain, providing imaging software for breast health diagnostics.
|
$105.91M |
$3.87
|
|
CGTX
Cognition Therapeutics, Inc.
CT1812 (zervimesine) is an orally delivered small-molecule therapeutic, the core product of the company.
|
$105.05M |
$1.20
+7.66%
|
|
ACOG
Alpha Cognition Inc. Common Stock
ZUNVEYL is Alpha Cognition's lead therapeutic targeting Alzheimer's disease.
|
$105.05M |
$6.50
+5.18%
|
|
HLVX
HilleVax, Inc.
Direct vaccine development activity with norovirus vaccine candidates (HIL-216.00) and existing vaccine focus.
|
$104.79M |
$2.09
|
|
BDSX
Biodesix, Inc.
Biodesix's Nodify and VeriStrat are blood-based diagnostic tests, i.e., liquid biopsy products.
|
$104.54M |
$13.10
-1.58%
|
|
DTIL
Precision BioSciences, Inc.
ARCUS is Precision BioSciences' in vivo gene editing platform and the lead programs PBGENE-HBV and PBGENE-DMD are built on this technology for therapeutic gene edits.
|
$104.46M |
$7.89
+4.85%
|
|
NTHI
Neonc Technologies Holdings, Inc.
Directly produces oncology-focused biotech therapies; lead programs NEO100/NEO212 targeting brain cancers.
|
$103.99M |
$5.29
+5.38%
|
|
PYXS
Pyxis Oncology, Inc.
Pyxis Oncology is a biotechnology company focused on oncology therapeutics, with MICVO as its lead asset in cancer.
|
$103.36M |
$1.67
-2.06%
|
|
CRDL
Cardiol Therapeutics Inc.
Cardiol Therapeutics' lead drug is a cardiovascular therapy targeting heart disease.
|
$103.34M |
$1.24
+11.71%
|
|
GOSS
Gossamer Bio, Inc.
Inhaled seralutinib represents a drug-delivery platform that concentrates therapy in the lungs to treat pulmonary hypertension, a major differentiator.
|
$103.23M |
$0.44
+1.60%
|
|
RPID
Rapid Micro Biosystems, Inc.
Growth Direct is a diagnostic equipment platform for automated microbial detection used in pharmaceutical QC.
|
$101.06M |
$2.29
+1.11%
|
|
AMWL
American Well Corporation
Amwell uses Carepoint and related hardware as part of its care-delivery ecosystem, aligning with medical devices/biometrics.
|
$100.19M |
$6.12
-1.13%
|
|
COYA
Coya Therapeutics, Inc.
The company's core focus on immunomodulatory Treg therapies places it squarely in immunology therapeutics.
|
$100.02M |
$4.79
+6.92%
|
Showing page 25 of 38 (3734 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
